

# Gallium citrate uptake is a marker of breast malignancy: true or false?

Muhammed A. Taher, Shanauk Navalkissoor, Andrew J.W. Hilson, John R. Buscombe

Department of Nuclear Medicine, Royal Free Hospital, London, United Kingdom

[Received 25 I 2007; Accepted 28 II 2007]

### Abstract

A 34-year old lady had a <sup>67</sup>Gallium citrate scan and demonstrated uptake by both of her breasts — diffuse in the right breast, but focal in the left breast at the "9 o'clock position". Core biopsy from both breasts showed fibroadenoma and no malignant cells were found. Though uptake of <sup>67</sup>Gallium citrate is normally associated with malignancy or infection there may be other causes of uptake and follow-up biopsy should be performed.

Key words: 67 Gallium citrate, breast adenoma

# Introduction

Gallium is a group III element in the Periodic Table with biological behaviour similar to iron. <sup>67</sup>Gallium citrate was developed as a bone-seeking radiopharmaceutical but found use clinically as a tumour-imaging and infection-seeking agent in range of tumours including lymphoma, melanoma, mesothelioma, bronchial carcinoma. Other non-cancerous causes of uptake was found to be infection or inflammation especially in , tuberculosis and active sarcoidosis. These infection-seeking property was noted in the early 1970s, and <sup>67</sup>Gallium citrate became the mainstay of infection scan for over a decade [1]. <sup>67</sup>Gallium binds avidly to the protein lactoferrin and visualization of the breasts of <sup>67</sup>Gallium citrate is commonly seen in pre-menopausal woman and is related to normal physiologic stimulation (puberty, postpartum, lactation) of the breast and increase in iron uptake. It has been reported in a small number of patients in the detection of breast cancer [2, 3].

Correspondence to: John Buscombe Nuclear Medicine Department, Royal Free Hospital Pond Street, London NW1 2QG, United Kingdom Tel: + 44 2-7 830 2470

e-mail: jbuscombe@medsch.ucl.ac.uk

# **Case report**

A 34-year non pregnant, non lactating woman with bilateral hilar lymphadenopathy was seen by a respiratory physician and had a suspected diagnosis sarcoidosis or lymphoma. A confirmatory <sup>67</sup>Gallium citrate scan was performed 48 hours after administration of tracer. This demonstrated intense uptake in both breasts — being more diffuse in the right breast, but focal in the left breast at 9 o'clock position (Figure 1). A CT scan of the breast showed that there was high density tissue within both breasts (Figure 2) and subsequent core biopsy from both breasts showed bilateral fibroadenoma with no malignant cells found. There was no evidence for a raised prolactin level.

### **Discussion**

In 1969 Edwards and Hayes noted on a bone scan the accumulation of <sup>67</sup>Gallium citrate in the cervical lymphnodes of a pa-




Figure 1. Asymmetric uptake of 67Ga-citrate in both breasts




Figure 2. Computed tomography scan showing markedly increased density of both breasts.

tient with Hodgkin's disease [4]. Higasi et al [5] used <sup>67</sup>Gallium citrate scanning in 149 patients with a variety of neoplasms and inflammatory lesions. They found six negative scans among the 16 cases of breast cancer and one false positive case among 19 cases of benign tumour, including six fibroadenomas and 13 cystic tumours — the false positive case was accompanied by inflammation which was thought to be the cause of the uptake of the <sup>67</sup>Gallium citrate and it was concluded that <sup>67</sup>Gallium citrate imaging is helpful only in advanced breast cancer or infection but no uptake was seen in benign breast tumours [6]. In hyperprolactinemia, 67Gallium citrate localizes in the breasts in a diffuse, bilaterally symmetrical pattern and not normally in the mixed diffuse and focal pattern seen in this patient. Other non-physiological causes for breast uptake of <sup>67</sup>Gallium citrate include certain medications such as cimetidine, infections including breast abscess, and primary or metastatic malignancies. Indeed it may be necessary to give women who are lactating specific radiation protection advice if the have a <sup>67</sup>Gallium citrate injection to prevent the child receiving a significant does for injected <sup>67</sup>Gallium labelled milk

# **Conclusion**

Though it has previously been reported that non-physiological uptake of <sup>67</sup>Gallium citrate in the breast if there is no endocrine disturbance is due to infection or malignancy it would appear that benign breast disease may also be a cause. Therefore, when unexplained breast uptake of <sup>67</sup>Gallium citrate is seen biopsy should be performed.

# **Acknowledgements**

Dr M.A. Taher was supported be a grant from the International Atomic Energy Agency and the British Council.

### References

- Ziessman HA, O'Malley JP, Thrall JH. Nuclear medicine: the requisites in radiology 3<sup>rd</sup> ed. Elsevier Mosby, Philadelphia 2006.
- Jing JM, Kim EE, Moulopoulos L et al. Primary breast lymphoma detected with SPECT using Gallium-67-citrate. J Nucl Med 1995; 36: 236–237.
- Dillehay GL, Papatheofanis F. Gallium imaging of tumors. In: Henkin RE, Boles MA, Dillehay GL, Halama JR, Karesh SM, Wagner RH, Zimmer AM (eds). Nuclear Medicine. Vol. II. Mosby-Year Book Inc., St. Louis 1996: 1463–1492.
- Edwards CL, Hayes RL. Tumor scanning with <sup>67</sup>Ga-citrate. J Nucl Med 1969; 10: 103–105.
- Higasi T, Nakayama Y, Murata A et al. Clinical evaluation of <sup>67</sup>Ga-citrate scanning. J Nucl Med 1972; 13: 196–201.
- Richman SD, Brodey PA, Frankel RS, deMoss EV, Tormey DC, Johnston GS. Breast scintigraphy with 99mTc-pertechnetate and <sup>67</sup>Gacitrate. J Nucl Med 1976; 16: 293.